Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of levornidazole disodium phosphate for pelvic anaerobic infection
ChiCTR2300073123Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levornidazole in Pelviabdominal infection, endometritis, Salpingitis and 5 more (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Clinical efficacy after 14 days of treatment. Started Nov 2017; status: completed.
02
Drugs
levornidazole
03
Conditions
Pelviabdominal infectionendometritisSalpingitisadnexitisTubo-ovarian abscess (TOA)
Beyond the preview
Go deeper on ChiCTR2300073123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073123.